Jazz Pharmaceuticals Expects $755 Million Actio Charge To Cut Third-Quarter EPS By About $11.00

The drugmaker estimates a non-deductible research charge from its Actio Biosciences purchase, which closed September 15.

Share
Jazz Pharmaceuticals Expects $755 Million Actio Charge To Cut Third-Quarter EPS By About $11.00

Jazz Pharmaceuticals, which develops medicines for rare diseases, expects a pre-tax charge of about $755 million in its third quarter for acquired in-process research and development tied to its purchase of Actio Biosciences, according to an 8-K filed Monday. The company estimates the charge will cut both standard-accounting and adjusted earnings per share by about $11.00.

A charge with no tax shield

Jazz said it completed the Actio acquisition on September 15, 2026. The charge covers in-process research and development, meaning research the company bought that has not yet become an approved product, and it is expensed up front.

The company said the charge is not tax deductible. It estimated the hit at about $11.00 per share on standard-accounting EPS and on adjusted EPS, the company's own measure that strips out items such as share-based compensation and intangible amortization.

The numbers are preliminary. Jazz said results for the quarter ended September 30, 2026, are not finalized and remain subject to its financial statement closing procedures, so actual figures could differ. The figures are unaudited and are not a substitute for the full quarterly financial statements.

The business behind the number

Jazz is an Irish drugmaker whose products treat sleep disorders, epilepsy and cancer. According to its 10-K for 2025, Xywav, for narcolepsy and idiopathic hypersomnia, made up 41% of net product sales that year, followed by Epidiolex at 26%, Rylaze at 10% and Zepzelca at 8%.

Its cancer portfolio also includes Ziihera and Modeyso.

Shares closed before the news

Jazz shares closed at $205.70 in Monday's session. The filing was accepted at 4:03 p.m. ET, after the close, so that price predates the disclosure.

Jazz's full third-quarter results, once its closing procedures are complete, will replace these estimates.

Sources

More on Jazz Pharmaceuticals

All Jazz Pharmaceuticals (JAZZ) coverage →